Premium
Current approaches to inhibition of proliferation in atherosclerosis
Author(s) -
Handley Dean A.
Publication year - 1985
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430060208
Subject(s) - platelet derived growth factor receptor , platelet derived growth factor , hyperplasia , smooth muscle , growth factor , vascular smooth muscle , connective tissue , intimal hyperplasia , cell growth , drug , medicine , cancer research , pharmacology , endocrinology , pathology , biology , receptor , biochemistry
Athersclerosis is characterized by progressive arterial stenosis of the major vessels of the systemic circulation. In man, atherosclerotic lesions are composed principally of smooth muscle cells, connective matrix derived from these cells, and variable amounts of lipid. Emphasized is the role of the platelet mitogen, platelet‐derived growth factor (PDGF), as a potent stimulus for the proliferation of smooth muscle cells in the development of atherosclerotic lesions. Animal models of proliferative atherosclerosis are reviewed, as are published references of approaches to inhibit smooth muscle cell hyperplasia in these models by drug administration. The results are discussed in terms of the potential therapeutic application of antiproliferative drugs designed to inhibit the mitogenic role of PDGF as a contributory factor in atherogenesis.